CURRENT REPORT
PURSUANT TO SECTION 13
OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported)
December 21, 2004
MedImmune, Inc.
(Exact
name of registrant as specified in its charter)
| Delaware | 0-19131 | 52-1555759 |
| (State or other jurisdiction of | (Commission File No.) | (I.R.S. Employer Identification No.) |
| incorporation or organization) |
One MedImmune Way,
Gaithersburg, MD 20878
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code (301) 398-0000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
MedImmune, Inc. (the “Company”) is currently party to a Part-Time Employment Agreement (the “Agreement”) with Melvin D. Booth, a director and former President and Chief Operating Officer of the Company, previously filed as Exhibit 10.53 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2003. The Agreement was, by its terms, scheduled to expire on December 31, 2004. On December 21, 2004, the Company entered into an amendment to the Agreement extending its term until June 30, 2005.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
/s/ William C. Bertrand, Jr. —————————————— William C. Bertrand, Jr. Vice President, General Counsel and Secretary |
Date: December 23, 2004